<DOC>
	<DOCNO>NCT02945267</DOCNO>
	<brief_summary>Background : Monotherapy S-1 , oral fluoropyrimidine , show non-inferiority gemcitabine overall survival ( OS ) good tolerability advance pancreatic cancer Asian patient . It also show nimotuzumab plus gemcitabine could improve OS progression free survival ( PFS ) patient unresectable pancreatic cancer . However , still unknown whether nimotuzumab plus S1 would improve OS PFS single S-1 . Maintenance treatment , new treatment pattern , also try patient first line treatment improve OS . Thus , study design compare nimotuzumab plus S1 placebo plus S1 maintenance treatment patient locally advance metastatic pancreatic cancer benefit first-line treatment gemcitabine combine nimotuzumab S1 ( complete response+partial response+stable disease ) . Patients method : 60 patient enrol , randomize 1:1 ratio group nimotuzumab plus S1 group placebo plus S1 . nimotuzumab/placebo : 400 mg/w , intravenous infusion , Infusion time ≥ 60 min , d1 , every two week . S1 : oral , 40 mg ( Body surface area &lt; 1.5 m2 ) 60 mg ( Body surface area &gt; 1.5 m2 ) , d1-d14 , every three week cycle . Treatment intervention stop condition disease progression intolerable toxic reaction participant ask quit . The primary endpoint time disease progression since randomization ( TTP ) , secondary point include OS , 3 year overall survival rate ( OSR ) safety .</brief_summary>
	<brief_title>Nimotuzumab Plus S1 Versus Placebo Plus S1 Maintenance Treatment Patients With Unresectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>1875 year ; Karnofsky Performance Status≥ 60 ; histologically prove locally advanced metastatic pancreatic cancer , unsuitable radiotherapy surgery resection ; benefit first line treatment gemcitabine plus nimotuzumab S1 ( complete response+partial response+stable disease ) ; least 4 week end firstline treatment ; least 1 measurable evaluable lesion ; anticipate survival≥12 week ; AST/ALT≤2.5 ULN ( ≤5 ULN patient hepatic metastasis ) ; total bilirubin≤2 ULN （≤3 ULN patient hepatic metastasis ) ; neutrophil count≥1.5×109/L ; platelet counts≥100×109/L ; hemoglobin level≥90 g/L ; creatinine clearance rate≥ 60 mL/min write informed consent previously receive following treatment : anticancer chemotherapy/molecularly target therapy palliative treatment , target chemotherapy progression , another interventional clinical trail within 4 week ; underwent major surgery within 4 week ; brain leptomeningeal metastasis ; history malignancy pancreatic cancer ; present symptomatic abdominal fluid need treatment ; serious disease diabetes , active infection ; know allergy anti epidermal growth factor receptor antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Maintenance Treatment</keyword>
</DOC>